Professor Ramon Shaban, Clinical Chair
Communicable Disease Control and Infection Prevention, Western Sydney Health Precinct
SYDNEY, AUSTRALIA
Bench Side Story continues with a Clinical Chair and Director of Communicable Disease Control and Infection Prevention at Western Sydney Local Health District,
Professor Ramon Z. Shaban, Clinical Chair and Director of Communicable Disease Control and Infection Prevention at the Western Sydney Local Health District, is the lead investigator and project director of the project which has received a 2022 MRFF (Medical Research Future Fund) Clinician Researchers – Nurse, Midwives and Allied Health grant for AUD$1.4 million.
You Might also like
-
Treatment pathways for chronic plantar heel pain
Jason Rogers is a Tasmanian physiotherapist clinician-researcher with a longstanding interest in improving musculoskeletal foot and ankle conditions. He completed his PhD at the Menzies Institute for Medical Research at the University of Tasmania in 2022 investigating the clinical and imaging factors associated with a common foot complaint known as chronic plantar heel pain.
-
In his father’s footsteps as a kidney transplant specialist
Since he was a young child, Dr Collins, has been interested in kidney failure and kidney transplants in particular. His father was also a kidney specialist, and he used to sit by the phone when his father, was on call and ringing people who were being offered a kidney transplant. The joy in their voices through this interaction created a lasting and profound impact on Dr Collins. This carried through his career and today he continues to seek better outcomes for Kidney patients.
-
Targeting chemotherapy resistance in ovarian cancer patients
Dr Alex Cole, from the Centenary Institute’s Centre for Biomedical AI, is now leading the research focused on developing a new treatment to counteract a protein called follistatin (FST), known for making ovarian cancer cells resistant to chemotherapy.
By employing cutting-edge molecular biology and directed evolution techniques, the project aims to create nanobodies—small, precise molecules—that can block FST. If successful, these nanobodies could enhance the effectiveness of chemotherapy and improve ovarian cancer treatment rates.